XML 23 R10.htm IDEA: XBRL DOCUMENT
v3.19.2

EARNINGS PER SHARE | 6 Months Ended
--- | ---
Jun. 30, 2019
Earnings Per Share, Basic and Diluted [Abstract] |
EARNINGS (LOSS) PER SHARE | EARNINGS PER SHARE The computation of basic and diluted earnings per common share was as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Amounts attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 206 |  |  | $ | 219 |  |  | $ | 370 |  |  | $ | 396 |
Income from discontinued operations, net of taxes | 20 |  |  | — |  |  | 20 |  |  | — |
Net income attributable to Quest Diagnostics’ common stockholders | $ | 226 |  |  | $ | 219 |  |  | $ | 390 |  |  | $ | 396 |
Income from continuing operations | $ | 206 |  |  | $ | 219 |  |  | $ | 370 |  |  | $ | 396 |
Less: Earnings allocated to participating securities | — |  |  | — |  |  | 1 |  |  | 1 |
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted | $ | 206 |  |  | $ | 219 |  |  | $ | 369 |  |  | $ | 395 |
Weighted average common shares outstanding – basic | 135 |  |  | 136 |  |  | 134 |  |  | 136 |
Effect of dilutive securities: |  |  |  |  |  |  |  |  |  |  |
Stock options and performance share units | 1 |  |  | 3 |  |  | 2 |  |  | 3 |
Weighted average common shares outstanding – diluted | 136 |  |  | 139 |  |  | 136 |  |  | 139 |
Earnings per share attributable to Quest Diagnostics’ common stockholders - basic: |  |  |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 1.52 |  |  | $ | 1.60 |  |  | $ | 2.74 |  |  | $ | 2.90 |
Income from discontinued operations | 0.15 |  |  | — |  |  | 0.15 |  |  | — |
Net income | $ | 1.67 |  |  | $ | 1.60 |  |  | $ | 2.89 |  |  | $ | 2.90 |
Earnings per share attributable to Quest Diagnostics’ common stockholders – diluted: |  |  |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 1.51 |  |  | $ | 1.57 |  |  | $ | 2.71 |  |  | $ | 2.84 |
Income from discontinued operations | 0.15 |  |  | — |  |  | 0.15 |  |  | — |
Net income | $ | 1.66 |  |  | $ | 1.57 |  |  | $ | 2.86 |  |  | $ | 2.84 |
The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Stock options | 5 |  |  | 2 |  |  | 5 |  |  | 2 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareBasicAndDilutedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration